Back to Evidence
Primary experimental recordNegative / threshold

PMC12830260::ACT034438

TXM-CB3

Evidence text

Paper-level observation

Fig. 6B: CB treatment in chronic phase did not improve locomotor activity, including total travel distance compared with the control group.
textConfidence: medium

Assay observation

Activity
Other
Subtype
Not reported by source
Measure
other
Comparator
=
Raw observation
did not improve locomotor activity cm
Normalized measurement
Not reported by source
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
Rattus norvegicus
Assay method
Not reported by source
Sequence
ACCPCNH
Standardization
ready simple
Assay conditions
"original_unit=cm"

Source publication

Thioredoxin-mimetic peptide attenuates epilepsy progression and neurocognitive deficits

Redox Biology · 2026

Related peptide identities

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.